255 related articles for article (PubMed ID: 26643930)
1. Effect of substituting IPV for tOPV on immunity to poliovirus in Bangladeshi infants: An open-label randomized controlled trial.
Mychaleckyj JC; Haque R; Carmolli M; Zhang D; Colgate ER; Nayak U; Taniuchi M; Dickson D; Weldon WC; Oberste MS; Zaman K; Houpt ER; Alam M; Kirkpatrick BD; Petri WA
Vaccine; 2016 Jan; 34(3):358-66. PubMed ID: 26643930
[TBL] [Abstract][Full Text] [Related]
2. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.
Asturias EJ; Bandyopadhyay AS; Self S; Rivera L; Saez-Llorens X; Lopez E; Melgar M; Gaensbauer JT; Weldon WC; Oberste MS; Borate BR; Gast C; Clemens R; Orenstein W; O'Ryan G M; Jimeno J; Clemens SA; Ward J; Rüttimann R;
Lancet; 2016 Jul; 388(10040):158-69. PubMed ID: 27212429
[TBL] [Abstract][Full Text] [Related]
3. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
[TBL] [Abstract][Full Text] [Related]
4. Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study.
Taniuchi M; Famulare M; Zaman K; Uddin MJ; Upfill-Brown AM; Ahmed T; Saha P; Haque R; Bandyopadhyay AS; Modlin JF; Platts-Mills JA; Houpt ER; Yunus M; Petri WA
Lancet Infect Dis; 2017 Oct; 17(10):1069-1079. PubMed ID: 28693854
[TBL] [Abstract][Full Text] [Related]
5. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants.
Wright PF; Connor RI; Wieland-Alter WF; Hoen AG; Boesch AW; Ackerman ME; Oberste MS; Gast C; Brickley EB; Asturias EJ; Rüttimann R; Bandyopadhyay AS
Lancet Infect Dis; 2016 Dec; 16(12):1377-1384. PubMed ID: 27638357
[TBL] [Abstract][Full Text] [Related]
6. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
[TBL] [Abstract][Full Text] [Related]
7. Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules.
Bandyopadhyay AS; Asturias EJ; O'Ryan M; Oberste MS; Weldon W; Clemens R; Rüttimann R; Modlin JF; Gast C
Vaccine; 2017 Dec; 35(52):7283-7291. PubMed ID: 29150209
[TBL] [Abstract][Full Text] [Related]
8. Comparison of IPV to tOPV week 39 boost of primary OPV vaccination in Indian infants: an open labelled randomized controlled trial.
Kanungo S; Kim DR; Haldar B; Snider C; Nalavade U; Kim SA; Park JY; Sinha A; Mallick AH; Manna B; Sur D; Nandy RK; Deshpande JM; Czerkinsky C; Wierzba TF; Petri WA; Ali M; Dey A
Heliyon; 2017 Jan; 3(1):e00223. PubMed ID: 28194449
[TBL] [Abstract][Full Text] [Related]
9. Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine-only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants.
Brickley EB; Wieland-Alter W; Connor RI; Ackerman ME; Boesch AW; Arita M; Weldon WC; O'Ryan MG; Bandyopadhyay AS; Wright PF
Clin Infect Dis; 2018 Oct; 67(suppl_1):S42-S50. PubMed ID: 30376086
[TBL] [Abstract][Full Text] [Related]
10. Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis.
Macklin GR; Grassly NC; Sutter RW; Mach O; Bandyopadhyay AS; Edmunds WJ; O'Reilly KM
Lancet Infect Dis; 2019 Oct; 19(10):1121-1128. PubMed ID: 31350192
[TBL] [Abstract][Full Text] [Related]
11. Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?
Resik S; Tejeda A; Mach O; Fonseca M; Diaz M; Alemany N; Heng Hung L; Aleman Y; Mesa I; Garcia G; Sutter RW
Clin Infect Dis; 2018 Oct; 67(suppl_1):S51-S56. PubMed ID: 30376088
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of poliovirus vaccines in chronically malnourished infants: a randomized controlled trial in Pakistan.
Saleem AF; Mach O; Quadri F; Khan A; Bhatti Z; Rehman NU; Zaidi S; Weldon WC; Oberste SM; Salama M; Sutter RW; Zaidi AK
Vaccine; 2015 Jun; 33(24):2757-63. PubMed ID: 25917673
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.
Sutter RW; Bahl S; Deshpande JM; Verma H; Ahmad M; Venugopal P; Rao JV; Agarkhedkar S; Lalwani SK; Kunwar A; Sethi R; Takane M; Mohanty L; Chatterjee A; John TJ; Jafari H; Aylward RB
Lancet; 2015 Dec; 386(10011):2413-21. PubMed ID: 26388534
[TBL] [Abstract][Full Text] [Related]
14. Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America.
Lopez-Medina E; Melgar M; Gaensbauer JT; Bandyopadhyay AS; Borate BR; Weldon WC; Rüttimann R; Ward J; Clemens R; Asturias EJ
Vaccine; 2017 Jun; 35(28):3591-3597. PubMed ID: 28455172
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial.
Sáez-Llorens X; Clemens R; Leroux-Roels G; Jimeno J; Clemens SA; Weldon WC; Oberste MS; Molina N; Bandyopadhyay AS
Lancet Infect Dis; 2016 Mar; 16(3):321-30. PubMed ID: 26719058
[TBL] [Abstract][Full Text] [Related]
16. Anomalous observations on IPV and OPV vaccination.
John TJ
Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.
Bandyopadhyay AS; Gast C; Rivera L; Sáez-Llorens X; Oberste MS; Weldon WC; Modlin J; Clemens R; Costa Clemens SA; Jimeno J; Rüttimann R
Lancet Infect Dis; 2021 Apr; 21(4):559-568. PubMed ID: 33284114
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan.
Saleem AF; Yousafzai MT; Mach O; Khan A; Quadri F; Weldon WC; Oberste MS; Zaidi SS; Alam MM; Sutter RW; Zaidi AKM
Vaccine; 2018 Mar; 36(13):1766-1771. PubMed ID: 29477307
[TBL] [Abstract][Full Text] [Related]
19. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial.
Anand A; Zaman K; Estívariz CF; Yunus M; Gary HE; Weldon WC; Bari TI; Steven Oberste M; Wassilak SG; Luby SP; Heffelfinger JD; Pallansch MA
Vaccine; 2015 Nov; 33(48):6816-22. PubMed ID: 26476367
[TBL] [Abstract][Full Text] [Related]
20. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba.
Cuba IPV Study Collaborative Group
N Engl J Med; 2007 Apr; 356(15):1536-44. PubMed ID: 17429085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
